| Literature DB >> 22292714 |
Gabriele Sales1, Enrica Calura, Duccio Cavalieri, Chiara Romualdi.
Abstract
BACKGROUND: Gene set analysis is moving towards considering pathway topology as a crucial feature. Pathway elements are complex entities such as protein complexes, gene family members and chemical compounds. The conversion of pathway topology to a gene/protein networks (where nodes are a simple element like a gene/protein) is a critical and challenging task that enables topology-based gene set analyses.Unfortunately, currently available R/Bioconductor packages provide pathway networks only from single databases. They do not propagate signals through chemical compounds and do not differentiate between complexes and gene families.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22292714 PMCID: PMC3296647 DOI: 10.1186/1471-2105-13-20
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Number of pathways converted to networks with average number of edges and nodes according to the selected database.
| Database | N. of pathways | Mean (Median) nodes | Mean (Median) edges |
|---|---|---|---|
| KEGG | 232 | 71.86 (54) | 211.12 (75.5) |
| Reactome | 1070 | 33.22 (14) | 780.64 (33) |
| BioCarta | 254 | 15.18 (14) | 36.88 (28) |
| NCI | 177 | 76.79 (48) | 165.18 (81) |
Figure 1Edges and nodes distribution of networks after pathway conversion according to the selected database.
Figure 2Toy examples of nodes with multiple elements converted to gene-network. Group AND (protein complexes, Panel A), group OR (member of gene family, Panel B) and compound mediated signal (panel C).
Frequency of compound chains that we propagate according to different databases.
| Chain length | KEGG | Reactome | Biocarta | NCI |
|---|---|---|---|---|
| 2 | 19790 | 55155 | 502 | 2790 |
| 3 | 0 | 874 | 9 | 134 |
| 4 | 0 | 736 | 8 | 11 |
| 5 | 0 | 140 | 0 | 0 |
| 6 | 0 | 39 | 0 | 0 |
| 7 | 0 | 6 | 0 | 0 |
| 8 | 0 | 17 | 0 | 0 |
| 9 | 0 | 1 | 0 | 0 |
Figure 3Differences in signal reconstruction of a selected portion of the insulin signaling pathway of KEGG (hsa04910). Panel A. The original signal cascade. Panel B. graphite signal reconstruction through chemical compound propagation. Numbers represent EntrezGene IDs. Panel C. KEGGgraph signal reconstruction.
Figure 4Catalysis and cleavage of Notch 1 by Gamma Secretase Complex. Reactome representation of the reactions (Panel A), BioPax information as it is stored in owl model and in Cytoscape plug-in BioPax dedicated (respectively panel B and C) and the graphite final network (panel D).
Figure 5Visualization of graphite network using RCytoscape package.
Figure 6Results of the simulation study on the Insulin signaling pathway compound mediated signal propagation. Panel A. Signal paths selected to be differentially expressed. Panel B. p-value distribution of the topological analysis SPIA (pPERT) with and without propagation. Panel C. graphite network obtained from insulin pathway with propagation. Panel D. network obtained from insulin pathway without propagation.
Pathway analysis performed using SPIA statistical test on graphite networks.
| Name | FDR | Signal | Database | BCR | ABL | |
|---|---|---|---|---|---|---|
| 1 | Leishmaniasis | 0.03 | Activated | KEGG | ||
| 2 | Phase 1 - Functionalization of compounds | 0.02 | Activated | Reactome | ||
| 3 | Syndecan-4-mediated signaling events | 0.00 | Activated | NCI | ||
| 4 | Regulation of RAC1 activity | 0.00 | Activated | NCI | ||
| 5 | RAC1 signaling pathway | 0.00 | Activated | NCI | ||
| 6 | RhoA signaling pathway | 0.00 | Activated | NCI | ||
| 7 | Regulation of RhoA activity | 0.00 | Activated | NCI | ||
| 8 | Noncanonical Wnt signaling pathway | 0.00 | Activated | NCI | ||
| 9 | Wnt signaling network | 0.00 | Activated | NCI | ||
| 10 | BCR signaling pathway | 0.00 | Inhibited | NCI | ||
| 11 | IL6-mediated signaling events | 0.00 | Inhibited | NCI | ||
| 12 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | 0.00 | Inhibited | NCI | ||
| 13 | Stabilization and expansion of the E-cadherin adherens junction | 0.00 | Activated | NCI | ||
| 14 | E-cadherin signaling in the nascent adherens junction | 0.00 | Activated | NCI | ||
| 15 | E-cadherin signaling events | 0.00 | Activated | NCI | ||
| 16 | HIF-1-alpha transcription factor network | 0.00 | Inhibited | NCI | ||
| 17 | ALK1 signaling events | 0.01 | Activated | NCI | ||
| 18 | Canonical Wnt signaling pathway | 0.02 | Activated | NCI | ||
| 19 | ALK1 pathway | 0.02 | Activated | NCI | ||
| 20 | S1P2 pathway | 0.02 | Inhibited | NCI | ||
| 21 | Regulation of nuclear SMAD2/3 signaling | 0.02 | Activated | NCI | ||
| 22 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | 0.02 | Activated | NCI | ||
| 23 | TGF-beta receptor signaling | 0.02 | Activated | NCI | ||
| 24 | C-MYB transcription factor network | 0.02 | Activated | NCI | ||
| 25 | Osteopontin-mediated events | 0.02 | Inhibited | NCI | ||
| 26 | Direct p53 effectors | 0.02 | Inhibited | NCI | ||
| 27 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | 0.03 | Activated | NCI | ||
| 28 | Regulation of nuclear beta catenin signaling and target gene transcription | 0.03 | Activated | NCI | ||
| 29 | S1P4 pathway | 0.03 | Inhibited | NCI | ||
| 30 | amb2 Integrin signaling | 0.03 | Activated | NCI | ||
| 31 | p38 MAPK signaling pathway | 0.04 | Activated | NCI | ||
| 32 | Posttranslational regulation of adherens junction stability and dissassembly | 0.04 | Activated | NCI | ||
| 33 | N-cadherin signaling events | 0.04 | Activated | NCI | ||
| 34 | Lissencephaly gene (LIS1) in neuronal migration and development | 0.05 | Activated | NCI | ||
| 35 | C-MYC pathway | 0.06 | Inhibited | NCI | ||
| 36 | p53 pathway | 0.06 | Activated | NCI |
Pathway analysis performed using topologyGSA statistical test on graphite networks.
| Name | FDR | Database | BCR | ABL | |
|---|---|---|---|---|---|
| 1 | CDO in myogenesis | 0.00 | Reactome | ||
| 2 | Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | 0.00 | Reactome | ||
| 3 | Role of Abl in Robo-Slit signaling | 0.00 | Reactome | ||
| 4 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 0.01 | Reactome | ||
| 5 | TNF signaling | 0.01 | Reactome | ||
| 6 | G1 Phase | 0.02 | Reactome | ||
| 7 | mTOR signalling | 0.02 | Reactome | ||
| 8 | PI3K Cascade | 0.02 | Reactome | ||
| 9 | Cyclin D associated events in G1 | 0.02 | Reactome | ||
| 10 | PI-3K cascade | 0.03 | Reactome | ||
| 11 | E2F mediated regulation of DNA replication | 0.04 | Reactome | ||
| 12 | Cyclin A/B1 associated events during G2/M transition | 0.04 | Reactome | ||
| 13 | Intrinsic Pathway for Apoptosis | 0.04 | Reactome | ||
| 14 | Extrinsic Pathway for Apoptosis | 0.05 | Reactome | ||
| 15 | Lissencephaly gene (LIS1) in neuronal migration and development | 0.00 | NCI | ||
| 16 | ErbB4 signaling events | 0.01 | NCI | ||
| 17 | Regulation of retinoblastoma protein | 0.00 | NCI | ||
| 18 | Canonical NF-kappaB pathway | 0.01 | NCI | ||
| 19 | p73 transcription factor network | 0.01 | NCI | ||
| 20 | Atypical NF-kappaB pathway | 0.02 | NCI | ||
| 21 | Neurotrophic factor-mediated Trk receptor signaling | 0.00 | NCI | ||
| 22 | Pathogenic Escherichia coli infection | 0.00 | KEGG | ||
| 23 | Chronic myeloid leukeamia | 0.00 | KEGG | ||
| 24 | Cell cycle | 0.0 | KEGG | ||
| 25 | Axon guidance | 0.00 | KEGG | ||
| 26 | Neurotrophin signaling pathway | 0.00 | KEGG | ||
| 27 | mtor signaling pathway | 0.01 | Biocarta | ||
| 28 | nf-kb signaling pathway | 0.01 | Biocarta | ||
| 29 | tnf/stress related signaling | 0.02 | Biocarta | ||
| 30 | p53 signaling pathway | 0.03 | Biocarta | ||
| 31 | tnfr1 signaling pathway | 0.02 | Biocarta | ||
| 32 | integrin signaling pathway | 0.02 | Biocarta | ||
| 33 | erk and pi-3 kinase are necessary for collagen binding in corneal epithelia | 0.02 | Biocarta | ||
| 34 | rb tumor suppressor/checkpoint signaling in response to dna damage | 0.03 | Biocarta | ||
| 35 | egf signaling pathway | 0.04 | Biocarta | ||
| 36 | tgf beta signaling pathway | 0.04 | Biocarta | ||
| 37 | role of mitochondria in apoptotic signaling | 0.04 | Biocarta | ||
| 38 | inhibition of cellular proliferation by gleevec | 0.04 | Biocarta | ||
| 39 | atm signaling pathway | 0.05 | Biocarta | ||
| 40 | influence of ras and rho proteins on g1 to s transition | 0.05 | Biocarta |
Figure 7Visualization of the chronic myeloid leukemia network of graphite, that contain BCR and ABL1 genes. Colors represent up or down regulated genes between positive and negative BCR/ABL rearrangement.